FDA approves first drug for rare skin disorder

The latest stories trending on MedCity News.

Editor's Pick

Top Story FDA Approves First Drug for Rare Skin Disorder, and It's a Redosable Gene Therapy Krystal Biotech's Vyjuvek is approved to treat recessive and dominant forms of dystrophic epidermolysis bullosa (DEB), a rare genetic skin disorder. The redosable gene therapy, applied to the skin, delivers a gene that gets cells to produce collagen that DEB patients lack.

Featured News

Report: Private Insurers Estimated To Pay $1.1B in Rebates in 2023 Individual market insurers are estimated to owe about $500 million in rebates to enrollees this year, a Kaiser Family Foundation analysis found. Small group market insurers are anticipated to owe about $330 million, and large group market insurers are expected to owe about $250 million. Moon Surgical Snags $55.5M for Its Robotic Laparoscopy Assistant Moon Surgical recently raised $55.5 million for its robotic surgical assistant, which has earned regulatory clearance in the U.S. and European Union. The startup also appointed Fred Moll, founder of Intuitive Surgical and Auris Health, as independent chair of its board.

Resources

How AI Helps Health Systems Improve the Quality of Care for Patients with Chronic Conditions Learn how Diagnostic Robotics' AI-powered care management solution helped a regional Blues plan and affiliated hospitals save $1,600 PMPM in cost of care reduction per engaged member by proactively targeting impactable patients and providing optimized care pathways. Download Now

MedCity News • PO Box 901 • New York, NY unsubscribe